'Varian cancer' diaporamas de présentation

755 views • 64 slides

Symptom Benefit ANZGOG-0701

Symptom Benefit ANZGOG-0701. Does Palliative Chemotherapy Improve Symptom Control in Platinum Resistant Ovarian Cancer. , START UP MEETING FOR STAGE 2. Response Rates in Phase 3 Trials. Patients with good PS entered into clinical trials- 2 nd Line Therapy. Symptom Benefit Study.

325 views • 19 slides

Study Schema

Study Schema. Target Population >18yrs platinum resistant/ refractory epithelial ovarian cancer / > 3 LINES ECOG 0-3 Able to commence treatment within 2wks of registration Sufficient English language skills to complete QoL forms independently. Stage1 50-100 patients

335 views • 15 slides

89 views • 1 slides